BioMarin制药公司看到投资者活动多种多样;公司打破了对收入的预期,并获得“机动购买”评级。 BioMarin Pharmaceutical saw varied investor activity; the company beat revenue expectations and has a "Moderate Buy" rating.

生物海洋制药公司在第四季度的投资者兴趣不尽相同,种子投资者有限公司减少了24.0%的股份,而XTX Topco有限公司增加了161.1%的股份. BioMarin Pharmaceutical Inc. saw mixed investor interest in Q4, with Seeds Investor LLC reducing its holdings by 24.0%, while XTX Topco Ltd increased its stake by 161.1%. 该公司最近报告称，净利润率为 14.96%，季度收入超出预期，达到 7.4731 亿美元。 The company recently reported a net margin of 14.96% and beat revenue expectations with a $747.31 million quarter. 分析师预测"中等购买"目标价格为94.00美元. Analysts predict a "Moderate Buy" with a target price of $94.00.